Get started
Live feed
·
PRReleasevia Quantisnow
Johnson & Johnson logo

Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule

ByQuantisnow·Wall Street's wire, on your screen.
JNJJohnson & Johnson
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track JNJ (Johnson & Johnson) and more on Quantisnow.